Bris­tol My­ers takes next big gam­ble on I/O fron­tier, pledg­ing near­ly $1.4B on Texas fir­m's tu­mor tox­ins

Bris­tol My­ers Squibb has made sev­er­al deals in im­muno-on­col­o­gy re­cent­ly, look­ing for po­ten­tial fol­low-ups to its block­buster drug Op­di­vo. And on Thurs­day, they made their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER